United States - English - NLM (National Library of Medicine)

cardinal health - ondansetron (unii: 4af302esos) (ondansetron - unii:4af302esos) - ondansetron 8 mg - the concomitant use of apomorphine with ondansetron is contraindicated based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron. ondansetron tablets and ondansetron orally disintegrating tablets are contraindicated for patients known to have hypersensitivity to the drug. animal studies have shown that ondansetron is not discriminated as a benzodiazepine nor does it substitute for benzodiazepines in direct addiction studies.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

organon pharma (uk) ltd - simvastatin; ezetimibe - oral tablet - 20mg ; 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

organon pharma (uk) ltd - simvastatin; ezetimibe - oral tablet - 40mg ; 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

organon pharma (uk) ltd - simvastatin; ezetimibe - oral tablet - 80mg ; 10mg

Australia - English - Department of Health (Therapeutic Goods Administration)

felton grimwade & bosisto's pty ltd - cupric sulfate pentahydrate, quantity: 98.24 microgram/ml (equivalent: copper, qty 25 microgram/ml); potassium iodide, quantity: 6.54 microgram/ml (equivalent: iodine, qty 5 microgram/ml); manganese sulfate monohydrate, quantity: 144 microgram/ml (equivalent: manganese, qty 46.7 microgram/ml); nicotinamide, quantity: 667 microgram/ml; thiamine hydrochloride, quantity: 667 microgram/ml; riboflavin sodium phosphate, quantity: 456 microgram/ml (equivalent: riboflavin, qty 333 microgram/ml); zinc gluconate, quantity: 2.48 mg/ml (equivalent: zinc, qty 333 microgram/ml); dexpanthenol, quantity: 667 microgram/ml; pyridoxine hydrochloride, quantity: 667 microgram/ml (equivalent: pyridoxine, qty 549 microgram/ml); iron (ii) glycinate, quantity: 2.92 mg/ml (equivalent: iron, qty 800 microgram/ml) - oral liquid - excipient ingredients: vanillin; silicon dioxide; citric acid monohydrate; sodium cyclamate; ascorbic acid; potassium sorbate; maltodextrin; caramel; glycerol; saccharin sodium; sorbitol solution (70 per cent) (non-crystallising); purified water; propyl gallate; xanthan gum; flavour - enhance/promote energy levels ; maintain/support energy levels ; helps enhance/promote general health and wellbeing ; maintain/support general health and wellbeing ; maintain/support (state vitamin/mineral/nutrient) levels in the body ; helps prevent dietary (state vitamin/mineral/nutrient) deficiency ; maintain/support (state vitamin/mineral) within normal range

Australia - English - Department of Health (Therapeutic Goods Administration)

felton grimwade & bosisto's pty ltd - thiamine hydrochloride, quantity: 667 microgram/ml; dexpanthenol, quantity: 667 microgram/ml; pyridoxine hydrochloride, quantity: 667 microgram/ml (equivalent: pyridoxine, qty 549 microgram/ml); cupric sulfate pentahydrate, quantity: 98.24 microgram/ml (equivalent: copper, qty 25 microgram/ml); sodium selenite pentahydrate, quantity: 5.55 microgram/ml (equivalent: selenium, qty 1.67 microgram/ml); eleutherococcus senticosus, quantity: 1.67 mg/ml (equivalent: eleutherococcus senticosus, qty 16.7 mg/ml); nicotinamide, quantity: 667 microgram/ml; zinc gluconate, quantity: 2.48 mg/ml (equivalent: zinc, qty 333 microgram/ml); riboflavin sodium phosphate, quantity: 456 microgram/ml (equivalent: riboflavin, qty 333 microgram/ml); manganese sulfate monohydrate, quantity: 144 microgram/ml (equivalent: manganese, qty 46.7 microgram/ml); potassium iodide, quantity: 6.54 microgram/ml (equivalent: iodine, qty 5 microgram/ml); ginkgo biloba, quantity: 334 microgram/ml (equivalent: ginkgo flavonglycosides, qty 89.178 microgram/ml; equivalent: ginkgolides and bilobalide, qty 22.378 microgram/ml; equivalent: ginkgo biloba, qty 16700 microgram/ml) - oral liquid - excipient ingredients: sodium cyclamate; citric acid monohydrate; glycerol; caramel; potassium sorbate; saccharin sodium; vanillin; sorbitol solution (70 per cent) (non-crystallising); purified water; xanthan gum; propyl gallate; flavour - enhance/promote energy levels ; maintain/support energy levels ; helps enhance/promote general health and wellbeing ; maintain/support general health and wellbeing ; maintain/support (state vitamin/mineral/nutrient) levels in the body ; maintain/support (state vitamin/mineral) within normal range ; traditionally used in western herbal medicine to maintain/support mental concentration/focus/clarity ; enhance/improve/promote/increase mental alertness/wakefulness ; maintain/support memory/mental recall

New Zealand - English - Ministry for Primary Industries

corteva agriscience new zealand limited - haloxyfop-p - haloxyfop-p 520 g/litre - herbicide

Australia - English - Department of Health (Therapeutic Goods Administration)

abbott medical australia pty ltd - 37265 - defibrillator, implantable, automatic, dual-chamber - the gallant dr model cddra500q dual chamber implantable cardioverter defibrillator (icd) monitors and regulates a patient?s heart rate and provides treatment of ventricular arrhythmias. incorporates the at/af detection algorithm indicated in patients with (or those at significant risk) of developing atrial tachyarrhythmias. this device is mr conditional. to provide ventricular antitachycardia pacing and ventricular cardioversion/defibrillation

Australia - English - Department of Health (Therapeutic Goods Administration)

abbott medical australia pty ltd - 35852 - defibrillator, implantable, automatic - the gallant model cdvra500q single chamber implantable cardioverter defibrillator (icd) monitors and regulates a patient?s heart rate and provides treatment of ventricular arrhythmias. this device is mr conditional. to provide ventricular antitachycardia pacing and ventricular cardioversion/defibrillation.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbott medical australia pty ltd - 47270 - biventricular pacemaker/defibrillator - the gallant hf model cdhfa500q cardiac resynchronisation defibrillator (crt-d) monitors and regulates a patient?s heart rate and provides treatment of ventricular arrhythmias. incorporates the at/af detection algorithm indicated in patients with (or those at significant risk) of developing atrial tachyarrhythmias. as a crt-d device, it is also indicated in certain patients with congestive heart failure. this device is mr conditional. to provide ventricular antitachycardia pacing, ventricular cardioversion/defibrillation and to resynchronise the right and left ventricles.